Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease
Microsatellite instability (MSI) is a widely studied molecular signature, which is associated with long-term benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be effective in the treatment of patients with MSI-positive colorectal cancer (CRC). Ana...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1492296/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539911560888320 |
|---|---|
| author | Daria Kravchuk Alexandra Lebedeva Alexandra Lebedeva Olesya Kuznetsova Olesya Kuznetsova Alexandra Kavun Anastasiia Taraskina Ekaterina Belova Ekaterina Belova Ekaterina Belova Tatiana Grigoreva Tatiana Grigoreva Egor Veselovsky Vladislav Mileyko Vladislav Mileyko Vladislav Nikulin Lidia Nekrasova Alexey Tryakin Mikhail Fedyanin Mikhail Fedyanin Mikhail Fedyanin Maxim Ivanov Maxim Ivanov |
| author_facet | Daria Kravchuk Alexandra Lebedeva Alexandra Lebedeva Olesya Kuznetsova Olesya Kuznetsova Alexandra Kavun Anastasiia Taraskina Ekaterina Belova Ekaterina Belova Ekaterina Belova Tatiana Grigoreva Tatiana Grigoreva Egor Veselovsky Vladislav Mileyko Vladislav Mileyko Vladislav Nikulin Lidia Nekrasova Alexey Tryakin Mikhail Fedyanin Mikhail Fedyanin Mikhail Fedyanin Maxim Ivanov Maxim Ivanov |
| author_sort | Daria Kravchuk |
| collection | DOAJ |
| description | Microsatellite instability (MSI) is a widely studied molecular signature, which is associated with long-term benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be effective in the treatment of patients with MSI-positive colorectal cancer (CRC). Analysis of serial liquid biopsy samples allows to detect changes in the tumor in response to therapy. Typically, somatic mutations are used for tracing the dynamics of the tumor, and the assessment of DNA signatures such as MSI is not currently used for these purposes. Here, we describe a case of a MSI-positive CRC, who received nivolumab monotherapy. Sequential sampling of the patient’s plasma demonstrated an increase in MSI burden (bMSI), which was found to correlate with the increase of driver mutation burden one month after starting nivolumab, and hyperprogressive disease. Thus, analysis of bMSI in liquid biopsy via NGS may be a promising method for timely assessment of the treatment effectiveness received by patients with MSI-positive CRC. |
| format | Article |
| id | doaj-art-8aa9a8df84394f7c95396af222066896 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8aa9a8df84394f7c95396af2220668962025-02-05T07:32:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14922961492296Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive diseaseDaria Kravchuk0Alexandra Lebedeva1Alexandra Lebedeva2Olesya Kuznetsova3Olesya Kuznetsova4Alexandra Kavun5Anastasiia Taraskina6Ekaterina Belova7Ekaterina Belova8Ekaterina Belova9Tatiana Grigoreva10Tatiana Grigoreva11Egor Veselovsky12Vladislav Mileyko13Vladislav Mileyko14Vladislav Nikulin15Lidia Nekrasova16Alexey Tryakin17Mikhail Fedyanin18Mikhail Fedyanin19Mikhail Fedyanin20Maxim Ivanov21Maxim Ivanov22Moscow Multidisciplinary Clinical Center “Kommunarka” of the Department of Health of the City of Moscow, State Budgetary Institution of Healthcare, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaInstitute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaN.N. Blokhin Russian Cancer Research Center, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaInstitute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, RussiaFaculty of Physics, Lomonosov Moscow State University, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaInstitute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaInstitute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, RussiaN.N. Blokhin Russian Cancer Research Center, Moscow, RussiaP. Hertsen Moscow Oncology Research Institute (MORI), Moscow, RussiaN.N. Blokhin Russian Cancer Research Center, Moscow, RussiaMoscow Multidisciplinary Clinical Center “Kommunarka” of the Department of Health of the City of Moscow, State Budgetary Institution of Healthcare, Moscow, RussiaN.N. Blokhin Russian Cancer Research Center, Moscow, RussiaFederal State Budgetary Institution “National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Health of the Russian Federation, Moscow, RussiaR&D Department, OncoAtlas LLC, Moscow, RussiaInstitute for Personalized Oncology, Sechenov First Moscow State Medical University, Moscow, RussiaMicrosatellite instability (MSI) is a widely studied molecular signature, which is associated with long-term benefit in patients treated with immune checkpoint inhibitor therapy. This approach has been proven to be effective in the treatment of patients with MSI-positive colorectal cancer (CRC). Analysis of serial liquid biopsy samples allows to detect changes in the tumor in response to therapy. Typically, somatic mutations are used for tracing the dynamics of the tumor, and the assessment of DNA signatures such as MSI is not currently used for these purposes. Here, we describe a case of a MSI-positive CRC, who received nivolumab monotherapy. Sequential sampling of the patient’s plasma demonstrated an increase in MSI burden (bMSI), which was found to correlate with the increase of driver mutation burden one month after starting nivolumab, and hyperprogressive disease. Thus, analysis of bMSI in liquid biopsy via NGS may be a promising method for timely assessment of the treatment effectiveness received by patients with MSI-positive CRC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1492296/fullcolorectal cancerliquid biopsyhyperprogressionnext-generation sequencingdMMR |
| spellingShingle | Daria Kravchuk Alexandra Lebedeva Alexandra Lebedeva Olesya Kuznetsova Olesya Kuznetsova Alexandra Kavun Anastasiia Taraskina Ekaterina Belova Ekaterina Belova Ekaterina Belova Tatiana Grigoreva Tatiana Grigoreva Egor Veselovsky Vladislav Mileyko Vladislav Mileyko Vladislav Nikulin Lidia Nekrasova Alexey Tryakin Mikhail Fedyanin Mikhail Fedyanin Mikhail Fedyanin Maxim Ivanov Maxim Ivanov Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease Frontiers in Immunology colorectal cancer liquid biopsy hyperprogression next-generation sequencing dMMR |
| title | Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease |
| title_full | Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease |
| title_fullStr | Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease |
| title_full_unstemmed | Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease |
| title_short | Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease |
| title_sort | dynamics of blood microsatellite instability bmsi burden predicts outcome of a patient treated with immune checkpoint inhibitors a case report of hyperprogressive disease |
| topic | colorectal cancer liquid biopsy hyperprogression next-generation sequencing dMMR |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1492296/full |
| work_keys_str_mv | AT dariakravchuk dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT alexandralebedeva dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT alexandralebedeva dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT olesyakuznetsova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT olesyakuznetsova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT alexandrakavun dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT anastasiiataraskina dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT ekaterinabelova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT ekaterinabelova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT ekaterinabelova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT tatianagrigoreva dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT tatianagrigoreva dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT egorveselovsky dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT vladislavmileyko dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT vladislavmileyko dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT vladislavnikulin dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT lidianekrasova dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT alexeytryakin dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT mikhailfedyanin dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT mikhailfedyanin dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT mikhailfedyanin dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT maximivanov dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease AT maximivanov dynamicsofbloodmicrosatelliteinstabilitybmsiburdenpredictsoutcomeofapatienttreatedwithimmunecheckpointinhibitorsacasereportofhyperprogressivedisease |